Chimerix · pitchdeck
Chimerix | Investor Presentation Deck | 43 slides
43 pages · 3 arc beats · 2 loops
Chimerix | Investor Presentation Deck | 43 slides
Chimerix · 2023-08 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
12468101214161820222426283032343638404243
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 38 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits — 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Agitate 9 slides 100% 9/9 slides 100% 9/9 slides · 42 hits — 0/9 slides
11.1% 1/9 slides 11.1% 1/9 slides 100% 9/9 slides 100% 9/9 slides Solution 28 slides 100% 28/28 slides 100% 28/28 slides · 127 hits — 0/28 slides
39.3% 11/28 slides 3.6% 1/28 slides 100% 28/28 slides 100% 28/28 slides Slide inventory
43 every slide · same image gating as the playbook
04
The slide uses a Gantt-style chart to represent drug development progress.plan_implementation
06
Includes a Kaplan-Meier survival curve, an anatomical illustration of tumor locations, and a comparative table of clinical outcomes.frame_problem
07
BICR = Blinded Independent Central Review; RANO = Response Assessment in Neuro-Oncology; HGG = High-Grade Glioma; LGG = Low-Grade Glioma; SAEs = Serious Adverseshow_traction
08
The slide details specific inclusion/exclusion criteria, including age, mutation status, prior therapy, and washout periods.plan_implementation
09
The slide highlights clinical trial results with specific response and disease control rates for two different RANO criteria.show_traction
10
The chart is a waterfall plot (often called a swimmer plot or spider plot in oncology, though technically a waterfall).show_traction
11
The chart is a waterfall plot showing Best % Change in SPD from Baseline. The legend indicates PS scores (060-100).analyze_data
12
The chart is a classic 'spider plot' used in oncology clinical trials to visualize individual patient tumor burden changes over time.show_traction
13
Data presented in two tables comparing healthy adult dose escalation vs glioma patient safety profiles.analyze_data
14
The slide highlights the correlation between RANO response criteria and improved clinical outcomes in H3 K27M-mutant DMG patients.show_traction
15
The table uses a color-coded heatmap to highlight favorable (green) vs unfavorable (pink) characteristics of clinical trial data.compare_peers
17
The slide uses a process flow diagram to illustrate the trial structure.plan_implementation
19
The slide details specific event counts and target hazard ratios for OS and PFS endpoints.analyze_data
20
The chart shows a dose-response curve where longer incubation times (48+ hours) result in higher efficacy (lower cell viability) at lower concentrations comparepresent_solution
22
The slide uses a medical illustration of the brain to map patient counts and positivity rates to specific anatomical regions.size_opportunity
25
Waterfall plot displays individual patient responses; PD indicates Progressive Disease threshold.show_traction
27
Includes a detailed biological pathway diagram showing mitochondrial and membrane-level interactions.present_solution
28
Includes citations to Chi et al. (2017) and Piccardo et al. (2019).present_solution
29
Includes a mechanism illustration, a bar chart of H3K27me3 levels, a Kaplan-Meier survival curve, and a dot plot of patient tumor data.show_traction
31
Includes molecular structure and protein target visualizations.present_solution
32
The slide uses a central human anatomical illustration to bridge the two distinct types of cancer models presented.show_traction
33
Includes logos for NIH and Pacific Pediatric Neuro-Oncology Consortium.show_traction
34
Includes an in vitro cell viability dose-response curve and a pharmacokinetic (PK) model showing plasma concentration over time.present_solution
35
The chart illustrates dose levels 1-11 with checkmarks indicating completed levels and a clear distinction between weekly and 3-day dosing regimens.show_traction
36
Uses a visual icon array to represent survival rates.size_opportunity
38
The slide uses a visual comparison of tumor burden in mice to demonstrate efficacy.present_solution
39
The chart shows a clear dose-response/timing-response relationship where earlier treatment leads to lower viral titers.show_traction